Influenza Vaccines

"Influenza Vaccines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more INFLUENZAVIRUS A and INFLUENZAVIRUS B strains.

Descriptor ID	D007252
MeSH Number(s)	D20.215.894.899.302
Concept/Terms	Influenza Vaccines Influenza Vaccines Influenza Vaccine Vaccine, Influenza Flu Vaccines Influenzavirus Vaccines Influenza Virus Vaccines Influenza Virus Vaccine Vaccine, Influenza Virus Virus Vaccine, Influenza High-Dose Trivalent Influenza Vaccine High-Dose Trivalent Influenza Vaccine High Dose Trivalent Influenza Vaccine Monovalent Influenza Vaccines Monovalent Influenza Vaccines Influenza Vaccines, Monovalent Vaccines, Monovalent Influenza Trivalent Influenza Vaccine Trivalent Influenza Vaccine Influenza Vaccine, Trivalent Vaccine, Trivalent Influenza Intranasal Live-Attenuated Influenza Vaccine Intranasal Live-Attenuated Influenza Vaccine Intranasal Live Attenuated Influenza Vaccine Universal Flu Vaccines Universal Flu Vaccines Universal Influenza Vaccines Trivalent Live Attenuated Influenza Vaccine Trivalent Live Attenuated Influenza Vaccine LAIV Vaccine Vaccine, LAIV Quadrivalent Influenza Vaccine Quadrivalent Influenza Vaccine Influenza Vaccine, Quadrivalent Vaccine, Quadrivalent Influenza

Below are MeSH descriptors whose meaning is more general than "Influenza Vaccines".

Chemicals and Drugs [D]
Complex Mixtures [D20]
Biological Products [D20.215]
Vaccines [D20.215.894]
Viral Vaccines [D20.215.894.899]
Influenza Vaccines [D20.215.894.899.302]

Below are MeSH descriptors whose meaning is more specific than "Influenza Vaccines".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Influenza Vaccines" by people in this website by year, and whether "Influenza Vaccines" was a major or minor topic of these publications.

Bar chart showing 63 publications over 18 distinct years, with a maximum of 7 publications in 2013

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2005	1	1	2
2006	1	0	1
2007	1	1	2
2008	1	0	1
2009	2	0	2
2010	4	1	5
2011	5	1	6
2012	2	0	2
2013	6	1	7
2014	6	0	6
2015	5	0	5
2016	2	1	3
2017	3	1	4
2018	3	0	3
2019	5	0	5
2020	3	0	3
2022	4	0	4
2023	2	0	2

Below are the most recent publications written about "Influenza Vaccines" by people in Profiles.

Katzman C, Morgan T, de Roche A, Harris J, Mauro C, Zimet G, Rosenthal S. Longitudinal assessment of COVID-19 vaccine uptake: A two-wave survey of a nationally representative U.S. sample. PLoS One. 2023; 18(10):e0289541.

View in: PubMed
Prioli KM, Akincigil A, Namvar T, Mitchell-Williams J, Schafer JJ, Cunningham RC, Fields-Harris L, McCoy M, Vertsman R, Guesnier A, Pizzi LT. Addressing racial inequality and its effects on vaccination rate: A trial comparing a pharmacist and peer educational program (MOTIVATE) in diverse older adults. J Manag Care Spec Pharm. 2023 Aug; 29(8):970-980.

View in: PubMed
Olson SM, Newhams MM, Halasa NB, Feldstein LR, Novak T, Weiss SL, Coates BM, Schuster JE, Schwarz AJ, Maddux AB, Hall MW, Nofziger RA, Flori HR, Gertz SJ, Kong M, Sanders RC, Irby K, Hume JR, Cullimore ML, Shein SL, Thomas NJ, Stewart LS, Barnes JR, Patel MM, Randolph AG. Vaccine Effectiveness Against Life-Threatening Influenza Illness in US Children. Clin Infect Dis. 2022 08 25; 75(2):230-238.

View in: PubMed
Abo Shama NM, Mahmoud SH, Bagato O, AbdElsalam ET, Alkhazindar M, Kandeil A, McKenzie PP, Webby RJ, Ali MA, Kayali G, El-Shesheny R. Incidence and neutralizing antibody seroprevalence of influenza B virus in Egypt: Results of a community-based cohort study. PLoS One. 2022; 17(6):e0269321.

View in: PubMed
Diaz-Arocutipa C, Saucedo-Chinchay J, Mamas MA, Vicent L. Influenza vaccine improves cardiovascular outcomes in patients with coronary artery disease: A systematic review and meta-analysis. Travel Med Infect Dis. 2022 May-Jun; 47:102311.

View in: PubMed
Ndeupen S, Bouteau A, Herbst C, Qin Z, Jacobsen S, Powers NE, Hutchins Z, Kurup D, Diba LZ, Watson M, Ramage H, Igyártó BZ. Langerhans cells and cDC1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 immune responses. PLoS Pathog. 2022 01; 18(1):e1010255.

View in: PubMed
Massoudi N, Mohit B. A Case-Control Study of the 2019 Influenza Vaccine and Incidence of COVID-19 Among Healthcare Workers. J Clin Immunol. 2021 02; 41(2):324-334.

View in: PubMed
Gotsman I, Shuvy M, Tahiroglu I, Zwas DR, Keren A. Influenza Vaccination and Outcome in Heart Failure. Am J Cardiol. 2020 08 01; 128:134-139.

View in: PubMed
Dbaibo G, Amanullah A, Claeys C, Izu A, Jain VK, Kosalaraksa P, Rivera L, Soni J, Yanni E, Zaman K, Acosta B, Ariza M, Arroba Basanta ML, Bavdekar A, Carmona A, Cousin L, Danier J, Diaz A, Diez-Domingo J, Dinleyici EC, Faust SN, Garcia-Sicilia J, Gomez-Go GD, Gonzales MLA, Hacimustafaoglu M, Hughes SM, Jackowska T, Kant S, Lucero M, Mares Bermudez J, Martin?n-Torres F, Montellano M, Prymula R, Puthanakit T, Ruzkova R, Sadowska-Krawczenko I, Szymanski H, Ulied A, Woo W, Schuind A, Innis BL. Quadrivalent Influenza Vaccine Prevents Illness and Reduces Healthcare Utilization Across Diverse Geographic Regions During Five Influenza Seasons: A Randomized Clinical Trial. Pediatr Infect Dis J. 2020 01; 39(1):e1-e10.

View in: PubMed
Innis BL, Berlanda Scorza F, Blum JS, Jain VK, Older Aguilar A, Post DJ, Roberts PC, Wairagkar N, White J, Bresee J. Meeting report: Convening on the influenza human viral challenge model for universal influenza vaccines, Part 1: Value; challenge virus selection; regulatory, industry and ethical considerations; increasing standardization, access and capacity. Vaccine. 2019 08 14; 37(35):4823-4829.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement